RWJ 58259

Drug Profile

RWJ 58259

Latest Information Update: 29 Jun 2006

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development; Millennium Pharmaceuticals
  • Developer Johnson & Johnson Pharmaceutical Research & Development LLC; Millennium Pharmaceuticals
  • Class Indazoles; Organic chemicals
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Vascular restenosis

Most Recent Events

  • 21 Mar 2002 COR Therapeutics has been acquired by, and integrated into, Millennium Pharmaceuticals
  • 27 Apr 2001 Preclinical development for Vascular restenosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top